AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Repligen Corporation sets 31 May 2012 as FDA Advisory Committee Date for SecreFlo NDA for improved pancreatic imaging.
(From M2 Equity Bites)
M2 EQUITYBITES-March 26, 2012-Repligen Corporation sets 31 May 2012 as FDA Advisory Committee Date for SecreFlo NDA for improved pancreatic imaging (C)1994-2012 M2 COMMUNICATIONS http://www.m2.com
Critical biologic company Repligen Corporation (NASDAQ:RGEN) said on Friday that the US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on 31 May 2012 to discuss its New Drug Application (NDA) for SecreFlo.
SecreFlo is indicated for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis, added the company.
…
